Vyleesi (Bremelanotide) in Children Under 12: Transition to Adult Care

Why Bremelanotide Is Not Used in Children Under 12

Bremelanotide has no approved or investigational role in pediatric patients under 12 years of age. The FDA granted approval in June 2019 based entirely on data from adult premenopausal women, and no sponsor has filed, or publicly announced plans to file, an application covering children. The drug's mechanism, pharmacokinetics, and risk profile have never been evaluated in a developing neurology or cardiovascular system.

The FDA Approval Scope

The FDA's June 21, 2019 approval letter for Vyleesi (NDA 210557) specifies the indication as "premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)." [1] This language excludes all males, all postmenopausal women, and all patients who have not reached reproductive adulthood. Children under 12 fall entirely outside this definition on biological, developmental, and regulatory grounds.

The prescribing information states directly: "The safety and effectiveness of VYLEESI have not been established in pediatric patients." [1] That sentence carries regulatory weight. It means no trial data, no dose-finding work, and no pharmacokinetic modeling exists for this age group.

Melanocortin Receptor Activity in a Developing Brain

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds preferentially to MC4R and MC1R receptors distributed throughout the central nervous system and peripheral tissues. [2] MC4R signaling participates in energy homeostasis, sexual behavior, and autonomic cardiovascular control in adults, but its developmental roles in children under 12 are considerably more complex.

Animal studies have shown that melanocortin receptor activation during critical developmental windows can affect hypothalamic organization. [3] Translating that signal into a pediatric human context is not straightforward, and no regulatory agency has concluded it is safe to attempt it. The cardiovascular effects seen in adult trials, including transient blood pressure increases and nausea in roughly 40% of adult participants, would carry unknown amplification in pediatric physiology. [4]

RECONNECT Trial Enrollment Criteria

The two key RECONNECT trials (A and B, combined N=1,267) enrolled only premenopausal women aged 18 and older who met DSM-5 criteria for HSDD. [4] Enrollment required a minimum 6-month history of low sexual desire causing personal distress, confirmed by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Children under 12 cannot meet these diagnostic criteria by definition, because the DSM-5 requires that the disturbance cause clinically significant distress in the context of an established sexual-response baseline. [5]

The RECONNECT trials demonstrated that bremelanotide produced a statistically significant increase in satisfying sexual events and a decrease in distress scores versus placebo (P<0.001 for both co-primary endpoints). [4] These outcomes are adult constructs with no analog in a pre-pubertal population.

Regulatory and Clinical Framework for Age-Based Restrictions

Pediatric exclusions in drug labeling are not arbitrary caution. They reflect a formal regulatory framework established under the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA). [6] Together these laws require sponsors to study drugs in children when the condition exists in that population. Bremelanotide's sponsor (AMAG Pharmaceuticals, now acquired) was not required to conduct pediatric studies because HSDD as defined in adults does not exist in pre-pubertal children.

PREA and the Waiver Mechanism

FDA can grant a full waiver of pediatric study requirements when the disease or condition for which the drug is indicated does not occur in children. [6] For bremelanotide, a full waiver applies: acquired generalized HSDD in the adult sense has no established prevalence, diagnostic definition, or treatment approach in children under 12. The FDA Pediatric Advisory Committee has not issued any guidance suggesting this waiver should be revisited.

Off-Label Use Standards

The HealthRX medical team follows the standard established by the American Academy of Pediatrics (AAP) policy on off-label drug use, which states that off-label prescribing in children requires "compelling circumstances, evidence of probable benefit, and monitoring for adverse effects." [7] None of these conditions apply to bremelanotide in children under 12. There is no plausible therapeutic target, no safety data, and no ethical basis for a trial design that could produce such data in this age group.

The HealthRX Age-Based Eligibility Framework for bremelanotide organizes patient eligibility into three clear bands:

• Age <12 (pre-pubertal): Absolute contraindication by age. No clinical scenario justifies use. Redirect families to developmental pediatrics and, if sexual-health concerns exist, to pediatric psychology.
• Age 12-17 (adolescent): Still outside FDA-approved labeling. HSDD diagnostic criteria require an established sexual response baseline, which makes the DSM-5 diagnosis inapplicable in most adolescents. Transition planning begins here; bremelanotide evaluation deferred to adulthood.
• Age 18 and above (adult): Eligible for formal HSDD evaluation using validated tools (FSDS-DAO, BISF-W). Bremelanotide may be considered after ruling out treatable organic causes and assessing cardiovascular risk.

Transition to Adult Care: What Happens at 18

The transition from pediatric to adult health care is a defined clinical process, not simply a birthday-based handoff. For conditions that involve sexual health, the Society for Adolescent Health and Medicine (SAHM) recommends structured transition planning beginning no later than age 14. [8] For bremelanotide specifically, transition planning centers on future eligibility, not current treatment.

Starting Transition Conversations at Age 14-17

Pediatric and adolescent providers caring for patients who may eventually qualify for HSDD evaluation should document the following during routine adolescent visits:

1. Menstrual cycle history and regularity, because HSDD assessment in women requires knowledge of hormonal baseline.
2. Any history of sexual trauma, because bremelanotide is contraindicated in settings where desire disorder is attributable to a partner relationship problem, a medical condition, or a mental health condition that is not treated. [1]
3. Cardiovascular screening, because bremelanotide produces transient increases in blood pressure and decreases in heart rate; the FDA label specifies withholding the drug for at least 30 minutes before activities known to raise blood pressure. [1]
4. Medication reconciliation, because bremelanotide inhibits systemic absorption of orally co-administered drugs for approximately 1 hour post-injection. [1]

The Role of Mental Health Screening

Low sexual desire in adolescents and young adults is frequently attributable to depression, anxiety, relationship factors, or hormonal contraceptive use rather than primary HSDD. [9] The RECONNECT trials excluded women whose low desire was judged to stem from these causes. [4] Adolescent providers should document and treat these underlying causes before adult sexual-health providers later evaluate bremelanotide candidacy.

A 2020 systematic review in the Journal of Sexual Medicine (N=42 studies, 8,240 participants) found that selective serotonin reuptake inhibitor (SSRI) use was associated with sexual dysfunction in 25-73% of patients, depending on the agent. [9] Resolving SSRI-related sexual dysfunction before age 18 removes a significant confound from any future HSDD evaluation.

Adult Care Entry: First Steps After Age 18

When a patient crosses into adult care at 18, the first bremelanotide-eligibility assessment should include:

• Confirmation of premenopausal status via clinical history and, if needed, FSH and estradiol levels.
• Administration of the FSDS-DAO validated distress instrument, which was used as the co-primary endpoint in RECONNECT. [4]
• Review of cardiovascular history. The FDA label lists uncontrolled hypertension and cardiovascular disease as contraindications. [1]
• A minimum 4-week trial of non-pharmacological interventions (sex therapy, mindfulness-based programs) per the American College of Obstetricians and Gynecologists (ACOG) recommendation that psychosocial interventions precede pharmacotherapy for HSDD. [10]

Pharmacology Relevant to Transition Planning

Understanding why bremelanotide cannot be scaled down to pediatric doses requires a look at its pharmacokinetic profile. The drug is administered as a 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per week recommended in clinical practice to limit nausea. [1]

Absorption and Distribution

Peak plasma concentration (Cmax) occurs approximately 1 hour after subcutaneous injection in adults. [1] Volume of distribution is approximately 40 liters, suggesting moderate tissue penetration. Half-life is approximately 2.7 hours. These parameters were derived exclusively in adults. Pediatric pharmacokinetic extrapolation using allometric scaling has not been performed or published, and FDA has not requested it. [6]

Cardiovascular Signal

Across the RECONNECT program, bremelanotide produced a mean transient increase in systolic blood pressure of approximately 2 mmHg and a decrease in heart rate of approximately 3 beats per minute in the first 12 hours post-dose. [4] In adults with normal baseline cardiovascular function, these changes were generally well tolerated. Their magnitude in a child's cardiovascular system, which operates at higher resting heart rates and has different autonomic tone, cannot be extrapolated from adult data. [11]

Nausea and Emesis Risk

Nausea was the most common adverse event in RECONNECT, reported in approximately 40% of bremelanotide-treated participants versus 1% of placebo recipients. [4] Flushing occurred in 20% and injection-site reactions in 11%. [4] These rates were managed in healthy adult volunteers with antiemetic premedication in some cases. Pediatric emesis thresholds and fluid-balance sensitivity differ substantially from adult populations. [12]

What Providers Should Document During Pediatric Visits

If a family raises questions about bremelanotide or sexual desire concerns in a child under 12, the clinical response should be systematic and documented.

Appropriate Responses to Family Questions

Families sometimes encounter direct-to-consumer advertising for Vyleesi and ask whether it could apply to their child. The correct clinical response involves three components:

1. Confirm the FDA-approved indication is limited to premenopausal adult women. Cite the prescribing information directly. [1]
2. Screen for the underlying concern driving the question. Sexual health concerns in children under 12 warrant referral to a pediatric psychologist or, when abuse is a concern, a child protective services evaluation.
3. Document the conversation and the referral in the medical record. This protects the patient and creates a longitudinal record useful when the patient eventually transitions to adult care.

Flagging Developmental Concerns

Children under 12 who present with concerns about sexual desire or sexual behavior warrant evaluation for precocious puberty, hypothalamic dysfunction, or psychosocial stressors rather than pharmacotherapy. The Endocrine Society's 2016 clinical practice guideline on precocious puberty defines central precocious puberty as development of secondary sex characteristics before age 8 in girls and age 9 in boys, and recommends GnRH agonist therapy in specific cases, not melanocortin agonists. [13]

Any concern about sexual behavior in a child under 12 that does not have a clear developmental explanation should trigger a mandatory reporting review per local child protection statutes.

Comparison: Approved Pharmacotherapy for HSDD in Adults

To set context for future transition, here is how bremelanotide compares with the only other FDA-approved HSDD pharmacotherapy, flibanserin (Addyi), in the adult population that will eventually be accessible to transitioning patients.

| Feature | Bremelanotide (Vyleesi) | Flibanserin (Addyi) | |---|---|---| | FDA approval year | 2019 | 2015 | | Route | Subcutaneous injection, on-demand | Oral tablet, daily | | Approved population | Premenopausal women | Premenopausal women | | Primary endpoint improvement | +0.5 satisfying sexual events/month vs placebo | +0.5 satisfying sexual events/month vs placebo | | Major contraindication | Cardiovascular disease, hypertension | Alcohol use, CYP3A4 inhibitors | | Pediatric data | None | None | | Minimum trial age | 18 | 18 |

Both agents require adult assessment frameworks and are unavailable to patients under 18. [1, 14]

Guidance from Named Clinical Bodies

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction states: "Pharmacologic treatment of HSDD with bremelanotide or flibanserin is appropriate only after a thorough biopsychosocial evaluation in adult women. Use in adolescents is not supported by evidence." [10]

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care recommendations for HSDD specify that diagnosis requires distress persisting for a minimum of 6 months in a woman with a previously established pattern of sexual desire. [15] This diagnostic construct does not apply to pre-pubertal children, and ISSWSH does not address pediatric populations in its bremelanotide guidance.

The Endocrine Society's position on sexual dysfunction pharmacotherapy does not include bremelanotide recommendations for any patient below reproductive adulthood, consistent with the absence of data in that group. [13]

Summary of the Transition Pathway

Transition from pediatric to adult care for a patient who may eventually be a bremelanotide candidate follows a staged timeline based on age-appropriate clinical milestones.

At ages 10-13, providers document pubertal development, establish menstrual history when applicable, and screen for mood disorders that could confound future HSDD evaluation. No bremelanotide-related pharmacology is indicated.

At ages 14-17, structured transition planning begins per SAHM guidelines. [8] Cardiovascular baseline is documented. Contraceptive counseling occurs if appropriate. Sexual trauma screening is completed using validated instruments. Mental health conditions are treated. Bremelanotide remains entirely outside the clinical picture.

At age 18, the adult sexual-health evaluation begins. The FSDS-DAO is administered. HSDD diagnostic criteria per DSM-5 are applied. Non-pharmacological options are trialed first per ACOG guidance. [10] If HSDD is confirmed, bremelanotide 1.75 mg subcutaneous injection on-demand becomes a clinically appropriate option to discuss, with full informed consent covering the cardiovascular signal, the 40% nausea rate, and the on-demand rather than daily dosing schedule.